公司活动 - 公司将于2025年10月28日至29日在巴哈马拿骚的Rosewood Baha Mar酒店参加Centurion One Capital第三届年度巴哈马峰会，这是一个为期两天的仅限受邀者参加的活动 [1] - 公司总裁兼首席执行官Dean Burns将在活动中进行演讲、参加投资者会议并参与小组讨论 [2] - 公司首席执行官表示，他非常期待在活动中向潜在投资者展示Ocumetics调节型人工晶状体的进展以及近期首次人体研究的结果 [2] 公司业务与产品 - 公司是一家加拿大研究和产品开发公司，致力于开发先进的视力矫正解决方案，旨在通过创新研发以最先进的人工晶状体和其他视力增强技术改变眼科领域 [4] - 公司目前正处于一项颠覆性眼科技术的首次人体早期可行性研究阶段 [5] - 公司开发的人工晶状体可植入眼睛的自然晶状体腔内，旨在通过眼睛的自然肌肉活动实现从远距到近距的焦点转换，从而无需眼镜或隐形眼镜即可在所有距离提供清晰视力 [5]

   Calgary, Alberta – TheNewswire - October 14, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce that it is holding a webinar to discuss the one-month patient results for its initial Group 1 patients that received the Ocumetics Accommodating Intraocular Lens (the “Ocumetics Lens”). Webinar details are as follows: Date: Thursday, October 15, 2025Time: 6:00 PM ET Join Ocumetics Director ...

 Calgary, Alberta – TheNewswire - October 8, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to report encouraging one-month safety and vision performance results for the first Group 1 patients that received the Ocumetics Accommodating Intraocular Lens (the “Ocumetics Lens”). “This again is a historic milestone for Ocumetics and for ophthalmology as a whole,” said Dean Burns, President and CEO of ...

Calgary, Alberta – TheNewswire - September 26, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce that the Company successfully completed its second surgical day in Mexico City as part of its ongoing clinical study evaluating the Ocumetics Accommodating Intraocular Lens (the “Ocumetics Lens”).All procedures were completed safely and without any reported issues or complications. These res ...

临床试验进展 - 公司已完成首批植入Ocumetics调节性人工晶状体患者的术后一个月检查，手术于2025年8月15日在墨西哥城进行 [1] - 术后检查于2025年9月12日进行，期间观察到患者恢复进展并完成了多项视力测量，临床报告分析及最新情况更新将很快提供 [2] - 公司的人体临床试验方案战略性地针对三个患者群体设计，目前正进行第一组患者的研究，第一组患者第二日也是最后一日的手术计划于2025年9月24日进行 [3] 产品技术与评估重点 - 公司处于眼科行业变革性技术的临床前研究阶段，其开发的人工晶状体可植入眼睛自然晶状体腔室，旨在无需矫正眼镜即可实现远近视力的清晰聚焦 [5] - 临床试验的主要终点包括安全性、远视力矫正、产品操作与手术交付以及近阅读能力评估 [7] - 公司是一家加拿大研发企业，致力于通过创新研发改变眼科领域，提供先进的视力矫正解决方案以提升患者生活质量 [4]

 Calgary, Alberta – TheNewswire - August 26, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce that it has completed the one-week postoperative examination of the first patients who were implanted with the Ocumetics Accommodating Intraocular Lens (the “Ocumetics Lens”).  All patients are recovering well, and no complications have been observed.  With this important milestone achieved, a ...